Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest photodynamic therapy Stories

2010-05-11 05:30:00

WILMINGTON, Mass., May 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010. Highlights for the first quarter include: Total product revenues were $8.7 million for...

2010-05-07 05:30:00

WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U(®), Blue Light Photodynamic Therapy Illuminator. The new patent will have...

2010-04-29 07:59:00

MONACO, April 29, 2010 /PRNewswire/ -- At the 10th Congress of the European Society for Photodynamic Therapy (Euro PDT), held in Monaco on March 12-13, 2010, Professor Lasse Braathen (Tromso, Norway), president of the Euro PDT, described the current state of topical photodynamic therapy, a revolutionary treatment for precancerous skin lesions and superficial skin carcinomas. He also underscored the major role played by the Euro PDT, whose objective is to promote research, development, and...

2010-03-09 07:30:00

WILMINGTON, Mass., March 9 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 22nd Annual OC Growth Stock...

2010-03-05 06:00:00

WILMINGTON, Mass., March 5 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(NASDAQ GM: DUSA), a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U(®) Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology (AAD) meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan(®) Kerastick(® )topical treatment, is an...

2010-03-03 05:30:00

WILMINGTON, Mass., March 3 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the fourth quarter and full year ended December 31, 2009. Fourth quarter and full year financial highlights include: The...

705d7e62f90907e120a44cfc138e8dbb
2010-02-03 11:20:00

In an advance with overtones of Star Trek phasers and other sci-fi ray guns, scientists in Canada are reporting development of an internal on-off "switch" that paralyzes animals when exposed to a beam of ultraviolet light. The animals stay paralyzed even when the light is turned off. When exposed to ordinary light, the animals become unparalyzed and wake up. Their study appears in the Journal of the American Chemical Society (JACS). It reports the first demonstration of such a light-activated...

2009-12-09 06:00:00

VANCOUVER, Dec. 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland. EVEREST is the first multi-center, double-masked, indocyanine green angiography (ICG-A) -guided randomized controlled trial with an angiographic treatment outcome designed to assess the effect of Visudyne(R) (verteporfin photodynamic...

a561f3c429b38d70e80b61fd3540fa0d1
2009-11-18 14:21:20

In an advance with overtones of Star Trek phasers and other sci-fi ray guns, scientists in Canada are reporting development of an internal on-off "switch" that paralyzes animals when exposed to a beam of ultraviolet light. The animals stay paralyzed even when the light is turned off. When exposed to ordinary light, the animals become unparalyzed and wake up. Their study appears in the Journal of the American Chemical Society (JACS). It reports the first demonstration of such a light-activated...

2009-11-10 05:30:00

WILMINGTON, Mass., Nov. 10 /PRNewswire/ -- The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer. This pilot study, which will also appear in the print version of the December issue of...